Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review by Mangel, Allen W & Hicks, Gareth A
© 2012 Mangel and Hicks, publisher and licensee Dove Medical Press Ltd. This is an Open Access article 
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical and Experimental Gastroenterology 2012:5 1–10
Clinical and Experimental Gastroenterology
Asimadoline and its potential for the treatment  
of diarrhea-predominant irritable bowel 
syndrome: a review
Allen W Mangel1
Gareth A Hicks2
1RTI Health Solutions, Research 
Triangle Park, NC, 2Tioga 
Pharmaceuticals Inc, San Diego, 
CA, USA
Correspondence: Allen W Mangel 
RTI Health Solutions, PO Box 12194, 
3040 Cornwallis Drive (FedEx),  
Research Triangle Park, NC 27709, USA 
Tel +1 919 485 5668 
Fax +1 919 541 7222 
Email amangel@rti.org
Abstract: Irritable bowel syndrome (IBS) is a multifactorial condition with principal symptoms 
of pain and altered bowel function. The kappa-opioid agonist asimadoline is being evaluated in 
Phase III as a potential treatment for IBS. Asimadoline, to date, has shown a good safety profile 
and the target Phase III population – diarrhea-predominant IBS patients with at least moderate 
pain – was iteratively determined in a prospective manner from a Phase II dose-ranging study. 
The clinical data in support of this population are reviewed in this article. Furthermore, the scien-
tific rationale for the use of asimadoline in the treatment of IBS is reviewed.   Considering the high 
patient and societal burdens of IBS, new treatments for IBS represent therapeutic advances.
Keywords: irritable bowel syndrome, kappa-opioid agonist, asimadoline, visceral pain, visceral 
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Introduction
Irritable bowel syndrome (IBS) remains one of the most common disorders seen by 
gastroenterologists.1–3 Although IBS itself does not lead to a more sinister pathology, 
the magnitude and importance of the symptoms associated with IBS result in patients 
undergoing more surgical procedures in search of other etiologies to explain and treat 
their symptoms, reduced quality of life, increased health care expenditures, increased 
work absenteeism, reduced productivity while at work, and increased psychological 
disorders.3–11 Thus, the burden of IBS on the patient and in terms of societal costs is 
large. Considering this, finding new, safe, and efficacious treatments for IBS is of 
large importance both at the patient level and also to reduce the overall burden on the 
health care system.
IBS has been estimated to have a prevalence of approximately 6%–12% in Western 
countries.9,12–14 Most studies show IBS to be a disorder predominantly in females, with 
a female-to-male ratio of 2–2.5 to 1. In many patients, symptoms begin in childhood 
or young adulthood, and often continue throughout their lives with an episodic course 
of exacerbations and remissions.
The principal symptoms of IBS are abdominal pain and altered bowel function.15 
The alterations in bowel function may manifest as diarrhea, constipation, or an 
alternation between the two bowel states. These abnormal bowel patterns have led to 
subtyping of IBS as diarrhea-predominant IBS (D-IBS), constipation-predominant IBS 
(C-IBS), and mixed or alternating IBS (A-IBS).15 As discussed later in this review, 
the abdominal pain associated with IBS is a consequence of a state of heightened 
visceral nociception.15
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Effective treatments for IBS need to improve both 
abdominal pain and abnormal bowel patterns. To date, few 
contemporary agents have obtained regulatory approval for 
the treatment of IBS. In considering a reasonable profile for 
future IBS treatments, several features should be noted. First, 
there should not be the expectation that a single agent will 
be efficacious in more than one subtype of IBS. Present-day 
agents have been shown to be efficacious in only one IBS sub-
type, reflecting that improvement by the same agent for states 
of both diarrhea and constipation is unlikely. This presents 
challenges for the treatment of the A-IBS   population. Some 
have proposed to study A-IBS patients in either their diarrhea 
or their constipated states, and then combine those popula-
tions with either D-IBS or C-IBS patients for indications 
of nonconstipated IBS patients or constipated IBS patients, 
respectively. We believe that to achieve these indications, 
it would be most appropriate to have completed long-term 
safety information both in D-IBS or C-IBS patients and in 
an all-comer population of A-IBS patients. A-IBS patients 
in their diarrheal phase will eventually alternate from their 
state of diarrhea to constipation; therefore, an all-comer 
A-IBS population should be used in safety studies. Second, 
effective IBS treatments must treat abdominal pain. Agents 
that treat only abnormal bowel function in IBS patients may 
be classified as laxatives or antidiarrheals, but are not IBS 
treatments just because they treat abnormal bowel function in 
IBS patients. Third, in evaluating datasets from randomized, 
placebo-controlled IBS studies, relevant subgroups should 
be considered. For all datasets in IBS patients, analyses 
should be conducted on patients stratified by gender and IBS 
subtype. Depending on the specific agent, other prespecified 
analyses may include efficacy by baseline pain. Finally, 
duration of action ideally should persist as long as treatment 
does. Some agents show a dissipation of effect with continued 
treatment. However, this latter point has not been and is not 
an absolute barrier to drug approval.
When evaluating currently available therapeutic options 
for the treatment of IBS, few drugs have regulatory approval. 
For D-IBS patients, alosetron remains the gold standard 
therapy with respect to drug efficacy. Alosetron shows 
excellent efficacy in the treatment of multiple symptoms 
of IBS in diarrhea-predominant patients.16,17 Most notably, 
improvement is seen on adequate relief of IBS pain and 
discomfort, urgency, stool consistency, and stool frequency. 
However, the potential use of alosetron will always be limited 
by its safety profile. With alosetron, significant constipation 
occurred in approximately 25% of the patients enrolled 
in clinical trials.17 Constipation was responsible for the 
withdrawal of approximately 10% of patients from clinical 
trials,17 and ischemic colitis was also reported in association 
with the use of alosetron.
The only other agent for which regulatory approval for 
D-IBS has been sought in contemporary time is rifaximin. 
Rifaximin shows marginal efficacy, with differences 
of rifaximin over placebo in the two pivotal studies of 
approximately 9% on the primary endpoint.18,19 Evaluation 
of abdominal pain also showed benefit of less than a 10% 
difference with rifaximin as compared with placebo. For 
several endpoints, efficacy with rifaximin dissipated over 
time in the 10-week observation period following 2 weeks of 
dosing. The initial new drug application (NDA) for rifaximin 
in the treatment of IBS was rejected due to lack of long-term 
safety or repeat-use data.
At the time of the writing of this manuscript, the kappa-
opioid agonist asimadoline is in Phase III development 
for the treatment of D-IBS patients. The available data on 
asimadoline as a potential treatment for IBS are reviewed 
in this manuscript.
For the treatment of C-IBS, tegaserod showed benefit 
on multiple symptoms in C-IBS patients,20,21 but tegaserod 
was ultimately withdrawn from marketing because of 
cardiovascular safety concerns. Lubiprostone is indicated 
for the treatment of patients with C-IBS. Efficacy with 
lubiprostone is not robust, with differences on the primary 
endpoint as compared with placebo of 7.8% (17.9% vs 
10.1%).22 Evaluation of data during the individual months of 
treatment showed significance in one Phase III study only at 
month 2, and in the other study at months 2 and 3. Magnitudes 
of improvement in pain were not clinically relevant.
Based on the publicly available data, we believe that 
linaclotide for the treatment of C-IBS will achieve regulatory 
approval. Linaclotide shows statistically significant benefit 
on multiple endpoints including bowel movement frequency, 
pain, straining, bloating, and stool consistency.23
Asimadoline: a peripherally 
restricted kappa-opioid  
receptor agonist
For a putative opioid agonist or antagonist, the importance 
of selectivity across opioid class receptors should not be 
underestimated. The effects and side effects of centrally 
active analgesic mu-opioid receptor agonists, such as 
euphoria, respiratory depression, tolerance, dependence, 
and withdrawal, can be significant, especially if agents are 
used as chronic treatments. Peripherally restricted mu-opioid 
receptor agonists (eg, loperamide) are powerful antidiarrheal 
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agents but do not show convincing analgesic activity.24 The 
kappa-opioid receptor agonist asimadoline, by contrast, 
produces both analgesic and antidiarrheal effects presumably 
via an action in the periphery. Activity in the central nervous 
system (CNS) is not necessary for efficacy of asimadoline in 
the treatment of IBS. When kappa-opioid agonists penetrate 
the CNS at sufficient levels, they do not produce the mu-like 
opioid side effects of respiratory depression or euphoria; 
however, kappa receptor activation in the CNS results in other 
undesirable adverse effects such as dysphoria, sedation, and 
diuresis.25 In the study of IBS, low levels of asimadoline are 
used such that these side effects do not occur.
Receptor binding and functional assays performed with 
asimadoline reveal it to be a potent, full agonist at kappa-
opioid receptors.26 A half-maximum inhibitory concentration 
(IC50) of 1.2 nM (Ki, 0.6 nM) was determined in radioligand 
binding assays using human recombinant kappa-opioid 
receptors expressed in CHO cells. Studies in preclinical spe-
cies revealed a similar high-affinity binding of asimadoline 
at guinea pig brain kappa receptors (IC50, 3–6 nM). Asim-
adoline is a potent, full agonist at kappa-opioid receptors 
in functional assays using rabbit vas deferens and guinea 
pig ileum.
Asimadoline is highly selective for kappa-opioid 
receptors, having approximately 400- to 500-fold lower 
affinity for recombinant human mu-opioid (IC50, 601 nM; 
Ki, 216 nM) or delta-opioid (IC50, 597 nM; Ki, 313 nM) 
receptors expressed in CHO cells.26 Studies in preclinical 
species revealed a similar high degree of selectivity for kappa 
receptors. Asimadoline is also highly specific, demonstrating 
no affinity below the micromolar range for any other receptor 
tested. Although arylacetamide kappa-opioid receptor 
agonists have been shown to block sodium channels at high 
concentrations,27 asimadoline is 500- to 1000-fold less potent 
in this activity than it is as a kappa-opioid receptor agonist,28 
which makes it highly unlikely that this activity has any 
relevance to the clinical effect of the drug at the IBS dose.
Following oral administration to rats, dogs, or monkeys, 
asimadoline is rapidly absorbed with a time to maximum 
plasma concentrations (Tmax) of 0.25 to 1 hour and an 
absolute oral bioavailability of 6%–20%.26,29 The drug 
is distributed with a half-life of 2–3 hours and has a 
terminal elimination half-life of 15–20 hours; steady 
state for twice-daily (bid) treatment occurs after 2–3 days 
(Tioga Pharmaceuticals, Inc, unpublished data). In 
humans following oral administration of single doses of 
0.15–15 mg, bioavailability is approximately 50%; maximum 
plasma concentrations (Cmax) are seen after 0.8–1.4 hours, 
and both Cmax and area under the curve (AUC) increased in 
a dose-proportional manner (Tioga Pharmaceuticals, Inc, 
unpublished data).30
Preclinical studies26,29 demonstrate that the distribution 
of asimadoline into tissues and organs is rapid, with 
concentrations several-fold higher than plasma in the liver, 
kidney, and lung. In contrast, less than 1% of total tissue 
concentration was found in the brain 1 hour following 
either single intravenous or oral doses.29 This very limited 
penetration of asimadoline into the CNS is in part due to its 
amphiphilic chemical structure, which limits its penetration 
across the blood-brain barrier, and in part because it is a 
substrate for P-glycoprotein (P-gp).26,29 Importantly, studies 
performed in nonclinical species31 and in man (Tioga 
Pharmaceuticals, Inc, unpublished data) have shown only 
minor increases in asimadoline exposure in the presence of 
powerful P-gp inhibitors; therefore, the risk from drug-drug 
interactions with drugs that are P-gp inhibitors is considered 
negligible.
Clinical pharmacodynamic studies in healthy volunteers 
provide further strong evidence for the limited CNS 
penetration of asimadoline. Diuresis is a class effect of 
kappa agonists in animals and humans mediated via actions 
both within the blood-brain barrier at the hypothalamic-
neurohypophyseal nerve terminal to inhibit release of 
antidiuretic hormone (ADH) and via a direct action in 
the kidney.32–35 In a placebo-controlled crossover study36 
of the effect of asimadoline on renal function in healthy 
volunteers, 5 mg and 10 mg single doses of asimadoline led 
to an increase in free water excretion (150–200 mL over the 
4-hour collection period post dose) without effect on urinary 
electrolytes. There was no concomitant inhibition of plasma 
ADH, suggesting that this aquaretic effect was not mediated 
centrally. However, under stimulated conditions of osmotic 
challenge, an inhibition of the enhanced plasma ADH 
was observed at the 10 mg dose, suggesting CNS activity 
of asimadoline at the 10 mg dose, 20-fold higher than the 
IBS dose.
A drug interaction study investigating the coadministra-
tion of asimadoline with the P-gp and CYP3A4 inhibitor 
ketoconazole was performed in healthy volunteers (Tioga 
Pharmaceuticals, Inc, unpublished data). Single (1.5 mg) and 
multiple (1.5 mg bid for 6 days) doses of asimadoline were 
administered in the presence of steady-state ketoconazole 
(200 mg bid for duration of a 10-day study). Assessment of 
potential CNS-mediated effects of asimadoline was made 
using several pharmacodynamic endpoints. A modest, two- 
to three-fold increase in AUC and Cmax of asimadoline was 
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observed with concomitant administration of ketoconazole. 
However, even in the presence of this enhanced exposure, 
equivalent to eight times the Cmax reached during 0.5 mg bid 
dosing (the target IBS dose), there were no effects upon any 
of the measured CNS endpoints. It was concluded that the 
threshold for CNS effects of asimadoline is at least ten-fold 
higher than drug levels achieved in the IBS setting, in good 
agreement with the experience from clinical safety and effi-
cacy studies performed to date.
Visceral analgesic  
and antihyperalgesic actions
Kappa-opioid receptors are members of the superfamily 
of inhibitory GTP-binding regulatory protein (G protein)-
coupled receptors, which activate potassium channels, inhibit 
calcium channels, and inhibit adenylate cyclase activity, all 
resulting in an inhibition of neuronal excitability.37–39 Kappa-
opioid receptors are thought to be located on the terminals 
of a variety of neurons, including those extrinsic visceral 
afferent neurons that transmit sensory signals from the gut 
to the CNS.40–45 A broad literature46 describes a peripherally 
mediated, visceral analgesic and antihyperalgesic activity of 
kappa-opioid receptor agonists.
The fundamental mechanism of action for production 
of the visceral analgesic effect of kappa-opioid receptor 
agonists is an inhibition of the excitability of visceral 
afferent nerve terminals in the gut wall, causing a reduction 
of action potential firing and neurotransmitter release 
from those sensory nerves.46 An action in the CNS does 
not appear to be necessary for visceral analgesia with 
kappa-opioid receptor agonists.41–43 However, the presence 
of visceral hypersensitivity is thought to be important for 
optimum visceral analgesic effect of kappa-opioid receptor 
agonists.45,47,48 The analgesic potency of asimadoline is 
increased in visceral pain models in the presence of visceral 
hypersensitivity.47,48 Previous studies in somatic pain 
models demonstrated that the potency of asimadoline’s 
analgesic effect is higher following the induction of 
hyperalgesia.26 Such antihyperalgesic effects may be 
produced by asimadoline’s abilities to reduce expression 
of substance P and calcitonin gene-related peptide in dorsal 
root ganglia (DRG) neurons in chronic hyperalgesia and to 
inhibit plasma extravasation and the release of neurogenic 
inflammatory mediators.26,49,50
Recently, data from studies of peripheral sen-
sory nerves (trigeminal ganglion) in rats suggest that 
peripheral kappa-opioid receptors require stimuli associ-
ated with sensitization processes to become functional.51 
Such induction of   “functional competence” of kappa-opioid 
receptors by   sensitizing agents (eg, bradykinin) involves the 
phospholipase C pathway, arachidonic acid metabolism, and 
membrane integrins. Earlier work described kappa-opioid 
receptors in peripheral sensory nerves as dormant “silent” 
receptors, showing that neuronal depolarization stimulates 
kappa-opioid receptor mRNA expression, axonal transport, 
and protein translation in DRG neurons.52–55 The authors 
described a membrane depolarization-induced de novo syn-
thesis of kappa-opioid receptors in DRG that was mediated 
by a netrin-1-induced translocation of mRNA to the tran-
scriptionally active polyribosomal fraction. The effect was 
dependent on calcium influx via L-type calcium channels, 
and Copb1-dependent trafficking of mRNA along axons was 
also demonstrated. Such neuronal activity-dependent and/or 
sensitization-dependent increases in kappa-opioid receptor 
expression and function may underlie the preferential effi-
cacy of asimadoline in hypersensitive states both in animal 
models and in man.
Pharmacodynamic studies with asimadoline also sug-
gest a preferential efficacy against visceral pain in patients 
with visceral hypersensitivity. Delvaux et al45 evaluated 
asimadoline for potential analgesic activity in IBS patients 
with significant pain symptoms and demonstrated visceral 
hypersensitivity (pain threshold #32 mmHg). The crossover 
study design compared the effect of single doses of placebo 
with 0.5 mg asimadoline upon distensions over a range of 
pressures up to 45 mmHg. Asimadoline produced a signifi-
cant reduction of the AUC of pain intensity (rated at each 
distension step) and a small but nonsignificant increase in 
pain threshold, compared with placebo. No effect on colonic 
compliance or perception of nonpainful distensions was 
observed. Delgado-Aros et al56 performed similar barostat 
studies in healthy volunteers. The parallel-group study 
compared single doses of placebo with 0.15 mg, 0.5 mg, 
and 1.5 mg asimadoline. Colonic distensions at 8 mmHg, 
16 mmHg, 24 mmHg, and 32 mmHg were rated for gas and 
pain perception scores using a 100 mm visual analogue scale 
(VAS). Although pain scores were lower in the 0.5 mg dose 
group at all distension levels, the differences were not sta-
tistically significant, including at the two higher pressure dis-
tension levels, which elicited pain scores of 40–50 mm on the 
VAS, suggesting that kappa receptor activation does not sig-
nificantly inhibit moderate to high-level noxious sensations in 
health. Asimadoline at 0.5 mg and 1.5 mg had mixed inhibi-
tory or excitatory effects on low-threshold gas and pain sensa-
tions in response to low pressure (8 mmHg and 16 mmHg) 
distension, which were scored below 35 mm on the VAS. This 
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suggests a potential role for kappa receptors in modulation of 
less noxious sensations in the “nonsensitized” state of health. 
The findings from these two studies correlate with the clinical 
experience gained to date from efficacy and safety studies 
with asimadoline, in which efficacy against symptoms of IBS 
is greatest in patients with a higher symptom burden.57
Antidiarrheal actions
Kappa receptors are found on cholinergic terminals of 
enteric neurons of the myenteric plexus where they inhibit 
cholinergic transmission and inhibit propulsive motil-
ity when studied in vitro.58,59 However, there is a paucity 
of data concerning any role of kappa-opioid receptors 
in gastrointestinal   secretion. Immunohistochemistry 
studies in gastrointestinal tissues from pig,60 rat,61 and 
guinea pig62 demonstrate a preferential distribution of 
kappa-opioid receptors in the myenteric plexus, with 
either low or no immunoreactivity found in submucous 
plexus neurons where mu-opioid receptors predominate. 
However, in mice the opposite distribution has been 
described for kappa-opioid receptors, along with an 
up-regulation of these receptors in the submucous plexus 
during inflammation.63 Asimadoline has no effect on normal 
gastrointestinal transit in the small intestine in mice26 or on 
colonic transit or postprandial   motility in healthy normal 
volunteers,56 but inhibits stress-induced fecal output in rats 
(Tioga Pharmaceuticals, Inc, unpublished data) and reduces 
diarrhea in D-IBS patients without producing constipation.57 
Thus, although kappa-opioid receptors are found in the ENS, 
they do not appear to be critical mediators of normal motil-
ity and secretory processes in the normal state. The lack of 
a constipating effect of kappa receptor agonists in D-IBS 
may be due to their preferential localization in the myen-
teric plexus such that secretory processes are not inhibited; 
in addition, their presynaptic localization may allow for a 
more subtle modulation of motility in contrast to the stronger 
inhibitory influence on both motility and secretion produced 
by the broader localization of mu-opioid receptors both 
presynaptically and on cell bodies of both myenteric and sub-
mucosal plexus neurons.60–62 In addition, a similar reliance 
upon a hypersensitizing stimulus for receptor functionality, 
as described above for peripheral sensory nerves, may exist 
in the ENS, especially in the submucous plexus.63
It is also possible that the effect of asimadoline on 
sensitized gastrointestinal transit may also be mediated by a 
non-ENS site of action. Several studies have demonstrated 
altered postprandial motility and symptoms in functional 
bowel disorder patients. Of note in D-IBS patients are 
increased small bowel motility,64 faster orocecal transit,65 
faster ileocolonic transit,66 increased colonic motility 
index, greater number of high amplitude propagating 
contractions and shortened colonic transit time,67 and 
increase in meal-related or postprandial symptoms.68 Such 
enhanced “gastrocolic” responses may be the result of 
hypersensitivity in the extrinsic vagal and or spinal nerves 
that mediate these reflexes, and inhibition of these enhanced 
reflexes is an interesting potential mechanism of action for 
asimadoline in the reduction of diarrhea and other symptoms 
in these patients.
Clinical trials with asimadoline  
in the treatment of IBS
Based on the results of the barostat study in IBS patients,45 
a randomized, multicenter, placebo-controlled, dose-ranging 
IBS trial was conducted with asimadoline.59,69 This Phase IIb 
trial enrolled approximately 600 patients, including patients 
with all three IBS subtypes, as well as male and female IBS 
patients. Prospectively defined subgroup analyses were 
done by degree of baseline pain, as well as by gender and 
IBS subtype.
In the intent-to-treat population, asimadoline at doses 
of 0.15 mg, 0.5 mg, or 1.0 mg was given bid and no dose 
level distinguished itself from placebo (bid). Following the 
prospectively planned analysis scheme, numerically and 
statistically significant benefit was seen with all doses of 
asimadoline in patients with higher levels of baseline pain.57,69 
One-third of the patients who entered the trial with the highest 
level of baseline pain showed excellent benefit on multiple 
endpoints. Similar benefit was seen in both genders, but effi-
cacy was driven by D-IBS patients. Thus, the Phase IIb study 
identified a target population for progression into Phase III 
of male and female D-IBS patients who had more severe 
pain at baseline. For ease of recruitment into the Phase III 
program, the target population became D-IBS patients with 
at least moderate pain at baseline. Analyses of this population 
from the Phase IIb data yielded excellent efficacy results on 
pain scores (Figure 1), stool frequency (Figure 2), pain-free 
days, urgency, bloating, and adequate relief.57
By contrast to the above study, a single-center study that 
analyzed data on the basis of on-demand or as-needed use 
did not show efficacy of asimadoline.70 The reason for the 
lack of efficacy is unclear.
Asimadoline has an extensive safety database.69,71 More 
than 1000 humans have been exposed to asimadoline in clini-
cal trials. Single doses of asimadoline as high as 15 mg and 
repeat doses up to 10 mg administered daily for up to 8 weeks 
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Figure 1 Effects of asimadoline on pain scores in D-IBS patients with at least moderate pain at baseline: asimadoline (asi) and placebo were administered twice daily for up to 
12 weeks. Pain scores were collected daily and averaged numerically on a weekly basis. Week 0 represents the 2-week baseline period. As is apparent, with 0.5 mg and 1.0 mg 
dose levels, a substantial reduction in pain occurred, compared with placebo. Copyright © 2008. Reproduced with permission from Alimentary Pharmacology & Therapeutics. 
Mangel AW, Bornstein JD, Hamm LR, et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2008;28(2):239–249.
Note: aP , 0.05; bP , 0.10.
Abbreviation: D-IBS, diarrhea-predominant irritable bowel syndrome.
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Figure 2 Effects of asimadoline (asi) on stool frequency in D-IBS patients with at least moderate pain at baseline: asimadoline (0.5 mg) and placebo were administered twice 
daily for up to 12 weeks. Stool frequency was collected daily and averaged numerically on a weekly basis. Week 0 represents the 2-week baseline period. As is apparent, with 
the 0.5 mg dose level a substantial reduction in stool frequency occurred, compared with placebo. 
Notes: Bars represent standard errors. Data provided by Tioga Pharmaceuticals, San Diego, CA. aP , 0.05; bP , 0.10.
Abbreviation: D-IBS, diarrhea-predominant irritable bowel syndrome.
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Table  2  Most  common  adverse  events  in  Phase  IIb  irritable 
bowel syndrome asimadoline trial among D-IBS patients with at 
least moderate pain at baseline
Adverse events Number of patients with adverse event 
(Asimadoline dose, twice daily)
Placebo  
(n = 30)
0.15 mg  
(n = 25)
0.5 mg  
(n = 23)
1.0 mg  
(n = 26)
Diarrhea 2 6 3 3
Sinusitis 1 1 1 3
Nausea 0 1 4 0
Abdominal pain 1 1 2 1
Headache 3 3 0 0
Dry mouth 0 0 1 2
Constipation 1 2 0 0
Dizziness 2 0 0 1
Fatigue 0 0 0 3
Note: Data provided by Tioga Pharmaceuticals, San Diego, CA. 
Abbreviation: D-IBS, diarrhea-predominant irritable bowel syndrome.
Table 1 Most common adverse events seen in nonirritable bowel 
syndrome asimadoline trials
Adverse event Percentage of patients with adverse event
Placebo  
(n = 224)
Asimadoline  
(0.15–2.0 mg/day)   
(n = 171)
Headache 8% 5%
Thirst 7% 5%
Nausea 4% 4%
Dizziness 4% 3%
Polyuria 2% 1%
Diarrhea 4% 2%
Fatigue 2% 1%
vomiting 1% 1%
Constipation* 0% 0%
Note: *Although no cases of constipation were reported, this is listed due to 
the  importance  of  constipation  in  a  D-IBS  population.  Data  provided  by  Tioga 
Pharmaceuticals, San Diego, CA.
Abbreviation: D-IBS, diarrhea-predominant irritable bowel syndrome.
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Figure 3 Proposed mechanism of action of asimadoline in the treatment of D-IBS. (A) The “brain–gut” axis in the normal state (health). Sensory information is conveyed 
to the brain via the spinal cord (cylinder) by extrinsic VAN. Local reflexes and descending regulatory input from the CNS via autonomic efferent nerves (not shown) 
control overall gut function. Normal secretomotor function is coordinated by the ENS. (B) visceral hypersensitivity in D-IBS drives increased activity in vAN resulting in 
increased sensory signaling to the brain and enhanced local reflexes, contributing to diarrhea. The accompanying transmitter release into the gut wall results in increased 
ENS activity (leading to diarrhea) and immune cell activation, which heightens sensitization. Kappa receptor expression on vAN terminals is up-regulated due to sensitization. 
(C) Asimadoline activates kappa-opioid receptors on VAN, leading to reduced sensory input to the brain, reduced local reflexes, and reduced transmitter release. Asimadoline 
also acts presynaptically to reduce neurotransmitter release in the ENS. Pain, diarrhea, and visceral hypersensitivity are reduced.
Abbreviations: CNS, central nervous system; D-IBS, diarrhea-predominant irritable bowel syndrome; ENS, enteric nervous system; vAN, visceral afferent nerves.
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have been evaluated in various Phase I and Phase II studies. 
With the dosage level being evaluated in the Phase III asim-
adoline program, 0.5 mg bid, a very good safety profile has 
been observed (Table 1). Significantly, for a drug intended to 
treat D-IBS patients, no increase in constipation was reported. 
The most common adverse events seen in the Phase IIb IBS 
trial are shown in Table 2 for the efficacy population being 
evaluated in Phase III. Constipation is once again included, as 
it is a significant adverse event to consider in D-IBS patients. 
No safety signals were observed.
Conclusion
Treatment of patients with IBS remains a perplexing problem. 
Several confounding factors contribute to the difficulties in 
developing therapeutics. IBS is a multifactorial condition 
with principal symptoms of pain and altered bowel function. 
Pain is always a difficult symptom to treat. Furthermore, 
IBS is subtyped into three principal groups, and the likely 
scenario is that the same medication will not work for more 
than one subtype of patients because of the difference in the 
type of bowel dysfunction. Additionally, although there are 
pharmacodynamic models by which to study transit and pain, 
there is no true animal model of IBS against which candidate 
therapeutics can be tested.
The kappa-opioid agonist asimadoline represents a 
potential treatment for IBS. Asimadoline, to date, has a 
good safety profile, and the target population showing strong 
efficacy was iteratively dissected from the Phase IIb data to 
optimize the likelihood of success in Phase III. There is a 
sound scientific basis for use of asimadoline in the   treatment 
of IBS. Although an action of asimadoline in the ENS can-
not be excluded, one potential mechanism of action that 
may explain all of the effects of asimadoline (on sensory 
and bowel function symptoms) in IBS is the activation 
of up-regulated kappa-opioid receptors on hypersensitive 
extrinsic afferent nerve terminals in the gut wall (Figure 3). 
This may result in (1) reduced sensory output from the gut to 
the spinal cord and brain, thereby directly inhibiting sensory 
symptoms and reducing augmented local motility reflexes 
that may contribute to sensory symptoms and diarrhea, and 
(2) reduced neurotransmitter release in the gut wall, which 
may lead to reduced diarrhea and potentially to a reduced 
level of peripheral, and subsequently central, sensitization 
in the brain–gut axis.
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